Key result
ACE inhibitors reduce progression to ESRD in non-diabetic renal disease.
Meta-Analysis
Answers are grounded in this paper and cite their sources.
ACE inhibitors merit first-line use in non-diabetic renal disease to delay ESRD; confirms renoprotection beyond BP reduction.
(2001) Ann Intern Med 135, 73. Jafar TH, Schmid CH, Landa M . , et al, for the ACE Inhibition in Progressive Renal Disease Study Group. . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. . Jul 17; . : . –87 . [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] QUESTION: In patients with non-diabetic renal disease, are antihypertensive regimens with angiotensin-converting enzyme (ACE) inhibitors effective for slowing the progression of disease? Studies were identified by searching Medline (May 1977 to September 1997), scanning abstracts in the proceedings of US and international conferences, scrutinising bibliographies from relevant articles, and contacting investigators for unpublished data. English-language randomised controlled trials were selected if they compared the effectiveness of antihypertensive regimens containing ACE inhibitors (enalapril, captopril, benazepril, cilazapril, and ramipril) with that of antihypertensive regimens not containing ACE inhibitors (control group) in patients with non-diabetic renal disease, and if they had ≥ 1 year of follow up. Data were extracted on sample size, patient characteristics, key components of the intervention, and outcomes. Main outcomes included end-stage renal disease (ESRD), defined as the initiation of long … [1]: {openurl}?query=rft.jtitle%253DAnnals%2Bof%2BInternal%2BMedicine%26rft.stitle%253DANN%2BINTERN%2BMED%26rft.issn%253D0003-4819%26rft.aulast%253DJafar%26rft.auinit1%253DT.%2BH.%26rft.volume%253D135%26rft.issue%253D2%26rft.spage%253D73%26rft.epage%253D87%26rft.atitle%253DAngiotensin-Converting%2BEnzyme%2BInhibitors%2Band%2BProgression%2Bof%2BNondiabetic%2BRenal%2BDisease%253A%2BA%2BMeta-Analysis%2Bof%2BPatient-Level%2BData%26rft_id%253Dinfo%253Adoi%252F10.7326%252F0003-4819-135-2-200107170-00007%26rft_id%253Dinfo%253Apmid%252F11453706%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.7326/0003-4819-135-2-200107170-00007&link_type=DOI [3]: /lookup/external-ref?access_num=11453706&link_type=MED&atom=%2Febmed%2F7%2F1%2F13.atom [4]: /lookup/external-ref?access_num=000169842300001&link_type=ISI
No takes yet. Share an insight, caveat, or question.
Jeffrey S. Berns (2002) conducted a meta-analysis in Non-diabetic renal disease. Angiotensin-converting enzyme (ACE) inhibitors vs. Antihypertensive regimens not containing ACE inhibitors was evaluated on End-stage renal disease (ESRD). Angiotensin-converting enzyme inhibitors reduce the progression of non-diabetic renal disease.
Synapse has enriched 10 related papers. Consider them for comparative context: